View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
September 9, 2021updated 10 Sep 2021 5:33pm

Novavax starts combined influenza and Covid-19 vaccine trial

Earlier in Phase III clinical trials, NVX-CoV2373 and NanoFlu have demonstrated strong results as standalone vaccines.

Novavax has initiated patient enrolment in a Phase I/II study of a combination vaccine using its seasonal influenza and Covid-19 vaccines.

The trial will be conducted in Australia at up to 12 study sites and aims to evaluate the safety and immunogenicity of the combination vaccine in 640 healthy adults.

It combines Novavax’ recombinant protein-based NVX-CoV2373 and NanoFlu vaccine candidates and saponin-based Matrix-M adjuvant in a single formulation known as the COVID-NanoFlu Combination Vaccine.

NVX-CoV2373 and NanoFlu have previously demonstrated strong results as standalone vaccines in Phase III clinical trials.

Novavax Research and Development president Gregory Glenn said: “This study is the first-of-its-kind to evaluate the vaccine’s potential to induce a robust immune response, augmented by our Matrix-M adjuvant, against two life-threatening diseases simultaneously.

“The combination of these two vaccines, which have individually delivered outstanding results with favourable safety and tolerability profiles, may lead to greater efficiencies for the healthcare system and achieve high levels of protection against Covid-19 and influenza with a single regimen.”

The trial will evaluate the safety, tolerability and immune response to NanoFlu formulated along with NVX-CoV2373 and Matrix-M adjuvant in adults aged 50 to 70 years.

It will enrol adults who have been either infected with the SARS-CoV-2 virus earlier or given an authorised vaccine at least eight weeks before enrolment.

For evaluating multiple formulations, all of them will be randomly assigned to cohorts and dosed on Day 0 and again at Day 56.

The trial results are expected during the first half of next year.

The COVID-NanoFlu Combination Vaccine demonstrated robust, functional immune responses in preclinical studies.

Last December, Novavax initiated a pivotal Phase III study of its Covid-19 vaccine candidate, NVX-CoV2373, in the US and Mexico.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy